# Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

Study · id `cardio:ct-nct06005597` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06005597](<https://clinicaltrials.gov/study/NCT06005597>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06005597

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 407 participants.

## Technical summary

Registry record NCT06005597. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-01 (actual); primary completion 2024-09-25 (actual). Results posted on 2025-10-08.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 407 participants (enrolled count; ClinicalTrials.gov record NCT06005597, source copy `cardio:ctgov-nct06005597-2025-10-08`, retrieved 2026-10-31)
- Started: 2024-03-01 (actual) (ClinicalTrials.gov record NCT06005597, source copy `cardio:ctgov-nct06005597-2025-10-08`, retrieved 2026-10-31)
- Primary completion: 2024-09-25 (actual) (ClinicalTrials.gov record NCT06005597, source copy `cardio:ctgov-nct06005597-2025-10-08`, retrieved 2026-10-31)
- Completion: 2024-10-16 (actual) (ClinicalTrials.gov record NCT06005597, source copy `cardio:ctgov-nct06005597-2025-10-08`, retrieved 2026-10-31)
- Results first posted: 2025-10-08 (ClinicalTrials.gov record NCT06005597, source copy `cardio:ctgov-nct06005597-2025-10-08`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT06005597, source copy `cardio:ctgov-nct06005597-2025-10-08`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06005597-2025-10-08`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
- Acronym: TANDEM
- Condition: Dyslipidemias
- Condition: Hypercholesterolemia
- Condition: Familial Hypercholesterolemia
- Condition: ASCVD
- Condition: High Cholesterol
- Intervention (Combination product): Combination Therapy
- Intervention (Drug): Monotherapy obicetrapib
- Intervention (Drug): Monotherapy ezetimibe
- Intervention (Other): Combination Therapy placebo
- Intervention (Other): Obicetrapib Placebo
- Intervention (Other): Ezetimibe Placebo
- Lead sponsor: NewAmsterdam Pharma
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Familial hypercholesterolemia (`cardio:familial-hypercholesterolemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: NewAmsterdam Pharma (`cardio:org-newamsterdam-pharma`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial (`cardio:pubmed-40347969`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a9f17d3376ce16ab2a6c66714847ff0b868fc9ea76a34e11669f83f15d769bd1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
